A5075730887- Immune cells in cancer
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Cell death mechanisms and regulation
- Sarcoma Diagnosis and Treatment
- S100 Proteins and Annexins
- Mesenchymal stem cell research
- Cancer-related gene regulation
- Bone health and treatments
- Wnt/β-catenin signaling in development and cancer
- Salivary Gland Disorders and Functions
- Cytomegalovirus and herpesvirus research
- NF-κB Signaling Pathways
- HER2/EGFR in Cancer Research
- Chemokine receptors and signaling
- interferon and immune responses
- Pancreatic function and diabetes
- Ubiquitin and proteasome pathways
- Cell Adhesion Molecules Research
- Peptidase Inhibition and Analysis
- Adenosine and Purinergic Signaling
- Bone and Joint Diseases
- PI3K/AKT/mTOR signaling in cancer
- Immune Response and Inflammation
OSE Immunotherapeutics (France)
2020-2025
Inserm
2012-2022
Nantes Université
2012-2022
Université Bretagne Loire
2018
La Ligue Contre le Cancer
2015-2016
Institut du Thorax
2012
Centre National de la Recherche Scientifique
2012
Background To improve the efficacy of bone marrow-derived mesenchymal stem cell (MSC) therapy targeted to infarcted myocardium, we investigated whether a self-setting silanized hydroxypropyl methylcellulose (Si-HPMC) hydrogel seeded with MSC (MSC+hydrogel) could preserve cardiac function and attenuate left ventricular (LV) remodeling during an 8-week follow-up study in rat model myocardial infarction (MI). Methodology/Principal Finding Si-HPMC alone, alone or MSC+hydrogel were injected into...
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous CD47 control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed preclinical models, therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, humans remains unknown. We report a potent...
Agonistic proresolutive monoclonal antibody reverses chronic inflammation.
Abstract The inflammatory response is a key mechanism for the elimination of injurious agents but must be tightly controlled to prevent additional tissue damage and progression persistent inflammation. C-type lectin receptors expressed mostly by myeloid cells play crucial role in regulation inflammation recognizing molecular patterns released injured tissues. We recently showed that receptor CLEC-1 able recognize necrotic cells. However, its acute following had not yet been investigated....
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients have not seen any major therapeutic progress in last 30 years, particular case of metastatic disease, which requires new strategies. The pro-apoptotic cytokine TNF-Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells while sparing normal cells, making it a promising tool several types cancer. However, certain cell lines appear resistant to recombinant human (rh) TRAIL-induced...
A numerous number of positive and negative signals via various molecules modulate T-cell activation. Within the transmembrane proteins, SIRPγ is interest since it not expressed in rodents. interaction with CD47 reevaluated this study. Indeed, we show that anti-SIRPγ mAb clone LSB2.20 previously used by others has been appropriately characterized. We reveal anti-SIRPα KWAR23 a Pan anti-SIRP which efficiently blocks SIRPα interactions CD47. expression on T cells varies their differentiation...
Abstract Immunocytokines are promising therapeutic approaches to enhance T cell response by delivering interleukins directly the tumor site. The fusion of wild-type or attenuated with anti-PD-1 antibodies has shown some efficacy in preferentially cis-activating PD1+ T-cells and lymph nodes. However, for many immunocytokines (e.g. IL-2/IL-15/IL-21/IL-12), off-target activation PD1-negative cells remains a significant challenge due high affinity cytokine their receptors, leading unwanted...
High-grade osteosarcomas are the most frequent malignant bone tumors in pediatric population, with 150 patients diagnosed every year France. Osteosarcomas associated low survival rates for high risk (metastatic and relapsed diseases). Knowing that canonical Wnt signaling pathway (Wnt/β-catenin) plays a complex but key role primary metastatic development of osteosarcoma, aim this work was to analyze effects ICG-001, CBP/β-catenin inhibitor blocking β-catenin dependent gene transcription,...
Abstract The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which enters the body principally through nasal and larynx mucosa progress to lungs tract. SARS-CoV-2 replicates efficiently in epithelial cells motivating development of alternative rapidly scalable vaccine inducing mucosal protective long-lasting immunity. We have previously developed an immunologically optimized multi-neoepitopes-based peptide platform has already demonstrated...
<h3>Background</h3> The c-type lectin receptor CLEC-1 is a pattern recognition receptor<sup>1</sup> expressed by endothelial and myeloid cells in mice, non-human primates, humans. While genetic deletion of mice does not lead to any developmental defect, or targeting using monoclonal antibodies increases damaged necrotic cell antigen cross-presentation cDC1 dendritic cells, as well subsequent T-cell activation anti-tumor response.<sup>2</sup> However, the identification endogenous ligands...
Abstract The c-type lectin receptor CLEC-1 is a pattern recognition [1] expressed by endothelial and myeloid cells in mice, non-human primates, humans. While genetic deletion of mice does not lead to any developmental defect, or targeting promotes anti-tumor response increasing cross-presentation necrotic damaged cDC1 dendritic enhancing T-cell activation [2]. To date, the identification endogenous ligand(s) their biological activity into remained be fully investigated. We aimed further...
Abstract Immunocytokines are promising new therapeutic approaches to enhance T-cell response by delivering interleukins into the tumoral site. Fusion of wild-type or attenuated anti-PD-1 antibody has shown some efficacy preferentially cis-activate PD1-expressing T-cells but on-target/off-tumor activity on PD-1-negative cells is still observed due high affinity cytokine its receptor leading a broad systemic effect, toxicity, clearance and low tumor biodistribution limiting potential...
Despite advances in clinical management, osteosarcoma and Ewing sarcoma, the two most frequent malignant primary bone tumors at pediatric age, still have a poor prognosis for high-risk patients (i.e., relapsed or metastatic disease). Triggering TRAIL pro-apoptotic pathway represents promising therapeutic approach, but previous studies described resistance mechanisms that could explain declining interest of such an approach trials. In this study, eight relevant human cell lines were used to...
10048 Background: Zoledronic Acid (ZA), a potent inhibitor of bone resorption is currently evaluated in phase III clinical trials Europe for the treatment malignant primary tumors. The beneficial effect liposomal form MuramylTriPeptide-Phosphatidyl Ethanolamine (MTP-PE, mifamurtide), activating macrophage population tumors, has also proved its efficacy osteosarcoma. objective our study was to evaluate safety combination zoledronic acid and mifamurtide pre-clinical models osteosarcoma before...
Abstract Chronic inflammation is associated with abnormal non-phlogistic clearance (efferocytosis) of apoptotic cells by macrophages and a defect the resolution pathways. The an active immunological process mediated specialized pro-resolving mediator (SPM) which target specific resolutive G-protein coupled receptors expressed different immune participate to tissue homeostasis return after injury. Defects in (chemotherapy-induced) tumor cell debris strengthens has been exacerbated growth...
Cancer immunotherapies by immune checkpoint blockade (CKI) has shown great therapeutic efficacy helping the system to recognize and attack cancer cells. However, a significant percentage of patients do not respond or develop resistance. T-cell exclusion from tumor core, mediated myeloid cells fibroblast colonizing micro-environment, been described as an important factor resistance inhibitors. Myeloid represent one most abundant cell types in many solid tumors are often associated with poor...
Abstract Cancer immunotherapies by immune checkpoint blockade (CKI) has shown great therapeutic efficacy helping the system to recognize and attack cancer cells. However, a significant percentage of patients do not respond or develop resistance. T-cell exclusion from tumor core, mediated myeloid cells fibroblast colonizing micro-environment, been described as an important factor resistance inhibitors. Myeloid represent one most abundant cell types in many solid tumors are often associated...
Abstract Osteosarcoma is the most common malignant bone tumor in pediatric population, representing around 4 cases per million people year world. Patient survival closely related to response of cells chemotherapy, reaching 70% at 5 years for patients with localized disease, but only 25% high-risk relapsed or metastatic disease. In 20% cases, have detectable metastases diagnosis, preferentially lungs, which a sign poor prognosis. However, it estimated that 80% pulmonary micrometastases,...
Abstract Myeloid cells represent one of the most abundant immune cell types in solid tumors that impede myeloid phagocytosis by triggering “don't eat me” and find signals. Recent literature demonstrates C-type lectin receptors (CLRs) are powerful pattern recognition shaping cell-mediated tissue damage positively or negatively regulating functions hence tumor elimination evasion. We previously reported orphan CLR CLEC-1 expressed dendritic (DCs) macrophages (MPs) is enhanced TGFβ tempers...